MAP2K7 and paraneoplastic neurologic syndrome: Despite the recent approval of selumetinib, a MEK inhibitor for symptomatic and inoperable PNs, it is not curative and it is unknown whether MEK inhibition prevents transformation of PNs to MPNSTs [4].